Triumph Cancer Institute Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 16-11-2024
- Paid Up Capital ₹ 0.50 M
as on 16-11-2024
- Company Age 6 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Profit 49.18%
(FY 2023)
- Ebitda 17.98%
(FY 2023)
- Net Worth -31.71%
(FY 2023)
- Total Assets %
(FY 2023)
About Triumph Cancer Institute
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Ramakant Deshpande and Sanjay Sharma serve as directors at the Company.
- CIN/LLPIN
U85300MH2018PTC307232
- Company No.
307232
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Mar 2018
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- LocationMumbai, Maharashtra
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Triumph Cancer Institute?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramakant Deshpande  | Director | 27-Mar-2018 | Current |
| Sanjay Sharma | Director | 26-May-2022 | Current |
Financial Performance and Corporate Structure Insights of Triumph Cancer Institute.
Triumph Cancer Institute Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 49.18% increase in profit. The company's net worth observed a substantial decline by a decrease of 31.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Triumph Cancer Institute?
In 2023, Triumph Cancer Institute had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Asian Oncology Private LimitedActive 8 years 3 daysRamakant Deshpande and Sanjay Sharma are mutual person
Asian Cancer FoundationActive 19 years 8 monthsRamakant Deshpande and Sanjay Sharma are mutual person
Asian Institute Of Oncology Private LimitedActive 21 years 11 monthsRamakant Deshpande and Sanjay Sharma are mutual person
Karnataka Leasing And Commercial Corporation LimitedActive 39 years 9 monthsRamakant Deshpande is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Triumph Cancer Institute?
Unlock and access historical data on people associated with Triumph Cancer Institute, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Triumph Cancer Institute, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Triumph Cancer Institute's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
_PRIVATE_LIMITED_354462.webp){kind=small}
